Sign in Create account

Viyash Scientific Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: VIYASH BSE: 512529
₹235.80
▼ -2.25 (-0.95%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
65/100
Moderate
Valuation
27/100
Expensive
Momentum
28/100
Bearish

QVM read Mixed signals Quality Moderate, Valuation Expensive, Momentum Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹10,302 Cr
PE (TTM)
166.1
Industry median 36.1 (152 companies)
Price to Book
3.3
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
8.25%
FII + DII, latest filed period
Piotroski Score
7
Relative return vs Nifty50, qtr %
-22.5
Relative return vs Sector, qtr %
-18.2
Free Cash Flow
₹188 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
382.35%
as of March 31, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
278.04%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
518.11%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
746.57%
as of March 31, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
779.97%
as of March 31, 2026
Industry median 14.05% (173 companies)
Current Ratio
2.38
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.14
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
11.96
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
5.91%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
8.29%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
9.07%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
3.29%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
8.42%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
4.88%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

4 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Piotroski F-score is 7 or more (score 7)
  • Yes Debt to equity is below 0.5 (0.14)
  • No Return on equity is 15% or more (4.9%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

1 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Undervalued (below its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-0.9%
Low 235.0500 · High 242.5000
1W return
-7.1%
Low 235.0500 · High 252.9500
1M return
-10.5%
Low 235.0500 · High 270.9500
52W return
21.0%
Low 178.1300 · High 298.0000
Lifetime High ₹323.6000 (June 29, 2021)
Lifetime Low ₹42.6500 (Oct. 9, 2018)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish1
Bearish5
5D
240.6
10D
244.6
20D
249.9
50D
255.6
100D
251.4
200D
231.9

Delivery and volume

Day avg. delivery
60.7%
Week avg. delivery
59.0%
Month avg. delivery
55.7%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

237.78
Pivot
First resistance240.52
Second resistance245.23
Third resistance247.97
First support233.07
Second support230.33
Third support225.62
Day RSI34.3
Day MFI28.4
Day MACD-6.11
Day MACD signal-4.71

Beta

1M1.53
3M1.48
1Y1.37
3Y1.33

Price change analysis

↓ -10.5%
Over 1 Month
LowHigh
235.05270.95
↓ -18.2%
Over 3 Months
LowHigh
235.05298.00
↑ 22.2%
Over 6 Months
LowHigh
186.00298.00
↑ 21.0%
Over 1 Year
LowHigh
178.13298.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 166.1 (own history: 194.9–4812.5)
Undervalued (below its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹354 Cr
Net profit (June 30, 2026)
₹21 Cr
Basic EPS (June 30, 2026)
₹0.4800

Ranks #44 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter61.31%
  • Mutual funds2.93%
  • FII/FPI4.50%
  • Other DII0.82%
  • Public30.35%

Largest holders

NameCategoryShares %Shares
CA HULL INVESTMENTSPromoter31.1700%136160231
CA HARBOR INVESTMENTSPromoter30.1400%131680103
HARIBABU BODEPUDIPublic2.7700%12099324
QUANT MUTUAL FUND - QUANT SMALL CAP FUNDPublic2.5800%11249836
KALIDINDI SRIHARI RAJUPublic2.3500%10262055

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 61.31% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 2.94% to 4.50% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 6.44% to 2.93% in Jun 2026 qtr

All shareholding details →

Insider trading, SAST & pledges

All 206 insider trades, 2 SAST, 111 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
26 Dec 2023 SEQUENT SCIENTIFIC EMPLOYEE STOCK OPTION PLAN TRUST Other Sell 0 ₹0
4 Apr 2022 Manish Gupta Director Sell 0 ₹0
4 Apr 2022 Manish Gupta Director Sell 0 ₹0
4 Apr 2022 Manish Gupta Director Sell 0 ₹0
4 Apr 2022 Manish Gupta Director Sell 0 ₹0
25 Mar 2022 Manish Gupta Director Sell 0 ₹0
25 Mar 2022 Manish Gupta Director Sell 0 ₹0
25 Mar 2022 Manish Gupta Director Sell 0 ₹0
11 Mar 2022 Manish Gupta Director Sell 0 ₹0
11 Mar 2022 Manish Gupta Director Sell 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 164 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
26 Aug 2026 NEO APEX SHARE BROKING SERVICES LLP Bulk Buy 4,163,047 264.7000 NSE
26 Aug 2026 NEO APEX SHARE BROKING SERVICES LLP Bulk Sell 4,163,047 266.1600 NSE
26 Aug 2026 MANSI SHARE AND STOCK BROKING PRIVATE LIMITED Bulk Sell 9,977,062 266.7700 NSE
26 Aug 2026 MANSI SHARE AND STOCK BROKING PRIVATE LIMITED Bulk Buy 9,807,102 264.6800 NSE
26 Aug 2026 KOTAK MAHINDRA MUTUAL FUND Bulk Buy 2,469,302 263.1000 NSE
26 Aug 2026 F3 ADVISORS PRIVATE LIMITED Bulk Sell 4,958,965 264.2600 NSE
26 Aug 2026 F3 ADVISORS PRIVATE LIMITED Bulk Buy 4,874,466 265.1200 NSE
26 Aug 2026 EDELWEISS MUTUAL FUND Bulk Buy 2,592,600 270.0000 NSE
26 Aug 2026 CA HULL INVESTMENTS Bulk Sell 12,264,022 265.4400 NSE
26 Aug 2026 CA HULL INVESTMENTS Bulk Sell 2,592,600 270.0000 NSE

All bulk and block deals →

Dividends

Full dividend history →
Ex-dateSubjectPer share (₹)Record date
8 Sep 2021 Dividend - Rs 0.50 Per Share 0.5000 10 Sep 2021
21 Aug 2019 Annual General Meeting/Dividend - Rs 0.20 Per Share 0.2000 —
20 Nov 2017 Interim Dividend - Re 0.20 Per Share 0.2000 21 Nov 2017

Corporate Actions

Full history (8 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from PI DRUGS & PHARMACEUTICALS LTD. to Sequent Scientific Limited
—NAME_CHANGEName changed from Sequent Scientific Limited to VIYASH SCIENTIFIC LIMITED
—NAME_CHANGEName changed from Visistha Traders & Finance Ltd to P.I. Drugs & Pharmaceuticals Ltd.
6 Apr 2018SCHEME_OF_ARRANGEMENT Scheme Of Arrangement
15 Sep 2016OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
11 Aug 2026 Financial Results Yes
19 May 2026 Financial Results/Dividend Yes
5 Feb 2026 Financial Results Yes
14 Nov 2025 Financial Results Yes
8 Aug 2025 Financial Results Yes

Corporate Announcements

All 730 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 Company Update Viyash Scientific Ltd - 512529 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
1 Oct 2026 Acquisition Viyash Scientific Limited has informed the Exchange about Completion of acquisition of BioForLife Italia S.r.l
28 Sep 2026 Insider Trading / SAST Viyash Scientific Ltd - 512529 - Closure of Trading Window
28 Sep 2026 Trading Window Viyash Scientific Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
18 Sep 2026 Company Update Viyash Scientific Ltd - 512529 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
18 Sep 2026 General Updates Viyash Scientific Limited has informed the Exchange about Allotment of ESOP
8 Sep 2026 Company Update Viyash Scientific Ltd - 512529 - Update On Proposed Acquisition Of Bioforlife Italia S.R.L
8 Sep 2026 General Updates Update on proposed acquisition of BioForLife Italia S.r.l
4 Sep 2026 General Updates Viyash Scientific Limited has informed the Exchange about ESOP Allotment
16 Aug 2026 Analysts/Institutional Investor Meet/Con. Call Updates Viyash Scientific Limited has informed the Exchange about Transcript

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.14)
  • Comfortable interest coverage (12.0x)
  • Healthy liquidity (Current Ratio 2.38)
  • Strong revenue growth YoY (780.0%)

Weaknesses

  • Low Return on Equity (4.9%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (166.1) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Viyash Scientific Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.